Intercept Pharma News Today

TODAY’S GAME PLAN: from the trading desk, this is not research DATA/HEADLINES 8:30ET Durable Goods Orders, Cap Goods Orders; 1:00ET 5 Year Auction TODAY’S HIGHLIGHTS: Border Patrol seized 2,700+ lbs. of fentanyl *between* ports of entry so far this year; enough lethal doses to easily wipe out the entire population of the USJoe Biden's dog

Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (NYSE:EDV) is estimated to report quarterly earnings at $0.37 per share on revenue of $784.53 million.

Intercept Pharma (ICPT – Research Report) received a Buy rating and a $19.00 price target from H.C. Wainwright analyst Ed Arce today. The ...

Primary Biliary Cholangitis is a rare, progressive, chronic autoimmune disease of the liver in which the small bile ducts are gradually destroyed, causing bile and other toxins to build up in the liver (known as cholestasis).

Akero Therapeutics Inc said on Monday data from a mid-stage study showed its experimental therapy reduced liver fat by 65% in certain patients with a type of fatty liver disease called nonalcoholic... | June 5, 2023

A panel of advisers to the U.S. Food and Drug Administration voted against approving Intercept Pharmaceuticals' (ICPT) investigational treatment for Nonalcoholic steatohepatitis, a serious progressive liver disease.

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Intercept Pharma (ICPT – Research Report), wi...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Intercept Pharma (ICPT – Research Report) on January 13 and set a price tar...